- Email: [email protected]
Cytotoxic Anticancer Agents
Annals of Oncology 30 (Supplement 6): vi57, 2019 doi:10.1093/annonc/mdz333
EDUCATIONAL LECTURE 6 : CYTOTOXIC ANTICANCER AGENTS EL6
Cytotoxic Anticancer Agents
While molecularly targeted drugs and immune checkpoint inhibitors are thriving cancer drugs, cytotoxic anticancer agents are still the basis for treatment of a lot of advanced malignancies. A combination of cytotoxic agents with an immune checkpoint inhibitor for non-small cell lung cancer is more effective than chemotherapy alone or
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz333/5582899/ by guest on 08 October 2019
Nagio Takigawa Kawasaki Medical School
an immune checkpoint inhibitor alone, and the value of cytotoxic agents has been reacknowledged. This presentation outlines the mechanism of action and classification of cytotoxic agents, and adverse events. That is, alkylating agents, antitumor antibiotics, platinum-containing agents, antimetabolites (fluorinated pyrimidine derivatives, cytidine derivatives, thymidine derivatives, purine antagonists, antifolates), topoisomerase inhibitors, and microtubule agonists (polymerization inhibitors and polymerization accelerators) are discussed.
EDUCATIONAL LECTURE 6 : CYTOTOXIC ANTICANCER AGENTS EL6
Cytotoxic Anticancer Agents
While molecularly targeted drugs and immune checkpoint inhibitors are thriving cancer drugs, cytotoxic anticancer agents are still the basis for treatment of a lot of advanced malignancies. A combination of cytotoxic agents with an immune checkpoint inhibitor for non-small cell lung cancer is more effective than chemotherapy alone or
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz333/5582899/ by guest on 08 October 2019
Nagio Takigawa Kawasaki Medical School
an immune checkpoint inhibitor alone, and the value of cytotoxic agents has been reacknowledged. This presentation outlines the mechanism of action and classification of cytotoxic agents, and adverse events. That is, alkylating agents, antitumor antibiotics, platinum-containing agents, antimetabolites (fluorinated pyrimidine derivatives, cytidine derivatives, thymidine derivatives, purine antagonists, antifolates), topoisomerase inhibitors, and microtubule agonists (polymerization inhibitors and polymerization accelerators) are discussed.